Company intelligence / Profile preview

Adaptimmune Therapeutics

Philadelphia, Pennsylvania, United States

Ownership: Public · ADAPY
Employees: ~506
Development stage: Other

Overview

Adaptimmune developed the first FDA-approved T cell receptor (TCR) therapy for cancer, with afamitresgene autoleucel (Tecelra) for metastatic synovial sarcoma, showing a 43% overall response rate in trials. Letetresgene autoleucel (lete-cel) has received FDA breakthrough therapy designation for myxoid/round cell liposarcoma and synovial sarcoma.

Therapeutic areas: OncologyHematology
Modalities: T cell receptor engineered T cell therapyCell therapyBiologic
Industry: Biotech

Drug pipeline

49 assets

ADP adoptive cell therapy

Approved

48 more assets in the full pipeline.

Request access →

Partnerships

AGC BiologicsUS WorldMeds

Financials

Market cap: $6.6M
Total revenue: $13.7M
Enterprise value: $29.2M

Beyond the preview

Go deeper on Adaptimmune Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adaptimmune Therapeutics.

Explore the full profile